Valuation: Cipla Limited

Market Cap 1,079B 11.2B 9.99B 9.31B 8.47B 15.96B 16.07B 113B 43.77B 551B 42.05B 41.15B 1,770B P/E 2027 *
26x
P/E 2028 * 21x
Enterprise Value 973B 10.1B 9.01B 8.4B 7.64B 14.39B 14.49B 101B 39.47B 497B 37.92B 37.1B 1,596B EV / Sales 2027 *
3.14x
EV / Sales 2028 * 2.73x
Free-Float
68.87%
Yield 2027 *
0.97%
Yield 2028 * 1.1%
1 day-0.71%
1 week-4.79%
Current month-1.42%
1 month-5.44%
3 months-9.15%
6 months+8.59%
Current year-17.26%
1 week 13.9
Extreme 13.9
14.4
1 month 13.9
Extreme 13.9
14.8
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
18.9
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
Director of Finance/CFO - 24/07/2026
President - 18/05/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 25/07/2014
Director/Board Member 71 30/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-4.79% - - 11.29B
+0.02%-3.52%+35.27%+111.11% 1,019B
-1.21%-6.99%+34.42%+60.96% 617B
+1.12%-0.20%+15.45%+80.24% 464B
-3.30%-6.15%+57.14%+34.69% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-3.62%+37.01%+52.02% 218B
-0.08%-4.98%+27.34%+93.61% 179B
Average -0.71%-3.54%+25.78%+57.40% 410.8B
Weighted average by Cap. -0.47%-3.54%+28.68%+68.60%

Financials

2027 *2028 *
Net sales 310B 3.22B 2.87B 2.67B 2.43B 4.58B 4.62B 32.31B 12.57B 158B 12.08B 11.82B 508B 347B 3.61B 3.22B 3B 2.73B 5.14B 5.17B 36.21B 14.09B 177B 13.54B 13.24B 570B
Net income 41.34B 429M 383M 357M 325M 611M 616M 4.31B 1.68B 21.1B 1.61B 1.58B 67.82B 51.51B 535M 477M 445M 405M 762M 768M 5.37B 2.09B 26.29B 2.01B 1.96B 84.51B
Net Debt -106B -1.1B -983M -915M -833M -1.57B -1.58B -11.06B -4.3B -54.14B -4.13B -4.05B -174B -131B -1.36B -1.22B -1.13B -1.03B -1.94B -1.96B -13.71B -5.33B -67.09B -5.12B -5.01B -216B
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
05/10/26 US$13.90 -0.71%
01/10/26 US$14.00 -0.71%
30/09/26 US$14.10 -2.08%
29/09/26 US$14.40 -0.69%
28/09/26 US$14.50 -0.68%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,335.50INR
Average target price
1,510.89INR
Spread / Average Target
+13.13%

Quarterly revenue - Rate of surprise